The authors have demonstrated the use of adenine base editors delivered via adeno-associated viruses to introduce edits in the mitochondrial genome. The manuscript describes the methodology well, and ...

ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science ...

NAD infusions are just one of the latest crazes for longevity-seekers, but can it really help you live longer? Here’s what an ...

A recent study by Chinese scientists has revealed the intricate molecular machinery driving energy exchange within ...

The implications of these advances are enormous. Recent studies show that rejuvenated RBCs have better survival rates and ...

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $80 price target on Beam Therapeutics (BEAM) shares after the company ...

Tools for advanced health treatments can help you fine tune your fitness and health goals. Try out DEXA scans, red light ...

“The real stroke of brilliance is the notion that you make the cell younger, and then it would be more resilient to injury,” ...

In the pursuit of better health and a longer life, science has uncovered powerful molecules that support cellular function and vitality.

ChromaDex Corporation’s CDXC share price has dipped by 10.06%, which has investors questioning if this is right time to buy.